Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

200 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Prehabilitation in Urology: Trial Update.
Rion C, Branger N, Maubon T, Rybikowski S, Pignot G, Walz J. Rion C, et al. Among authors: pignot g. Eur Urol Focus. 2024 Jan;10(1):8-10. doi: 10.1016/j.euf.2023.10.011. Epub 2023 Oct 24. Eur Urol Focus. 2024. PMID: 37884402
A Giant Paratesticular Liposarcoma: Case Report and Literature Review.
Caviglia A, Beverini M, Pacchetti A, Branger N, Pignot G, Bertucci F, Walz J. Caviglia A, et al. Among authors: pignot g. Case Rep Oncol. 2023 Mar 23;16(1):162-166. doi: 10.1159/000528221. eCollection 2023 Jan-Dec. Case Rep Oncol. 2023. PMID: 36970715 Free PMC article.
Active surveillance of low-grade prostate cancer using the SurACaP Criteria: A multi-institutional series with a median follow-up of 10years.
Leclercq L, Bastide C, Lechevallier E, Walz J, Charvet AL, Gondran-Tellier B, Campagna J, Savoie PH, Long-Depaquit T, Daniel L, Rossi D, Pignot G, Baboudjian M. Leclercq L, et al. Among authors: pignot g. Fr J Urol. 2024 Mar;34(2):102571. doi: 10.1016/j.fjurol.2024.102571. Epub 2024 Feb 4. Fr J Urol. 2024. PMID: 38717459
Preparing for the Worst: Management and Predictive Factors of Open Conversion During Minimally Invasive Renal Tumor Surgery (UroCCR-135 Study).
Branger N, Doumerc N, Waeckel T, Bigot P, Surlemont L, Knipper S, Pignot G, Audenet F, Bruyère F, Fontenil A, Parier B, Champy C, Rouprêt M, Patard JJ, Henon F, Fiard G, Guillotreau J, Beauval JB, Michel C, Bernardeau S, Taha F, Mallet R, Panthier F, Guy L, Vignot L, Khene ZE, Bernhard JC. Branger N, et al. Among authors: pignot g. Eur Urol Open Sci. 2024 Mar 28;63:89-95. doi: 10.1016/j.euros.2024.03.009. eCollection 2024 May. Eur Urol Open Sci. 2024. PMID: 38585592 Free PMC article.
Perioperative dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin in muscle-invasive bladder cancer (VESPER): survival endpoints at 5 years in an open-label, randomised, phase 3 study.
Pfister C, Gravis G, Flechon A, Chevreau C, Mahammedi H, Laguerre B, Guillot A, Joly F, Soulie M, Allory Y, Harter V, Culine S; VESPER Trial Investigators. Pfister C, et al. Lancet Oncol. 2024 Feb;25(2):255-264. doi: 10.1016/S1470-2045(23)00587-9. Epub 2023 Dec 21. Lancet Oncol. 2024. PMID: 38142702 Clinical Trial.
200 results